The introduction of several novel radionuclides and radiopharmaceuticals have significantly improved the treatment of metastatic bone pain and neuroendocrine and other malignant or non-malignant tumors. This article summarizes the current approaches and futures prospects of some known therapeutic radionuclides. Radionuclide therapy has the advantage of delivering a highly concentrated absorbed dose to the targeted tumor while sparing the surrounding normal tissues.
The non-invasiveness of the procedure and relatively low toxicity in comparison to conventional chemotherapy and external beam radiotherapy make radionuclides an attractive therapy in the management of benign and malignant diseases. To date, an increasing number of new antibodies have been studied in clinical trials and have shown positive evidence of efficacy. The clinical outcomes of some radionuclides are discussed in the…
